Mesoblast

Mesenchymal stromal cell therapeutics

MESO · Nasdaq · Australia / United States

Share price · MESO

$11.64-5.03 (-30.17%) 3M

close as of 2026-11-18 · 24h delayed · vol 133K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MESO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026+17.0%
  2. 19 Oct 2026-10.0%
  3. 27 Aug 2026+8.0%
  4. 17 Aug 2026+9.1%
  5. 15 Jul 2026+9.0%
  6. 13 Jul 2026+5.1%
  7. 26 Jun 2026-9.0%
  8. 25 Jun 2026-6.8%
  9. 7 Apr 2026-7.9%

    Nothing announced by MESO that day or the session before.

  10. 5 Mar 2026+7.5%

    Nothing announced by MESO that day or the session before.

Share of unusual movement by asset

For each asset, the share of MESO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
rexlemestrocel-L
events and moves
2shown from 8 days
remestemcel-L (Ryoncil)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—43%
Sessions with no dated event—45%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
remestemcel-L(Ryoncil)
Approved
Allogeneic MSC therapyCell therapy
Inflammatory Bowel DiseaseGraft-versus-Host Disease
Ulcerative Colitis, Crohn's Disease
Phase 3
Mesenchymal precursor cells (MPCs)Cell therapy
Heart FailureChronic Low Back Pain

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
rexlemestrocel-LPhase 3Degenerative Disc Disease
Est. primary completion 2027-07 · NCT06325566 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
remestemcel-L · RyoncilPhase 3GVHD - Graft-Versus-Host Disease
Est. primary completion 2028-02-28 · NCT07568535 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 June 2026Filing submittedrexlemestrocel-LMesoblast received a BLA filing number and requested modular review for rexlemestrocel-L in LVAD patients
US, FDA · Source ↗

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
FY2026-Q3$30M—$122M$4.1Mreport ↗
View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q1$1.9M$7.1M$49M$19M-$16M operating cash flowreport ↗
2022-Q4$2.1M$7.7M$68M$24M-$16M operating cash flowreport ↗
2022-Q3$1.5M$5.7M$86M$17M-$14M operating cash flowreport ↗
2022-Q1$2.0M$8.3M$77M$21M-$15M operating cash flowreport ↗
2021-Q4$2.4M$10M$95M$26M-$17M operating cash flowreport ↗
2021-Q3$3.6M$9.3M$116M$23M-$20M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$17M$35M$162M$26M-$50M operating cash flowreport ↗

Mesoblast reported revenue of $17.2M for fiscal year 2025, up 191.5% YoY, with R&D spend of $34.81M, up 37.3% YoY. Cash and equivalents stood at $161.55M, and the company reported a net loss of $102.14M, with a quarterly net burn of $102.14M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.9M$25M$63M$22M-$48M operating cash flowreport ↗
2023-FY$7.5M$27M$71M$20M-$63M operating cash flowreport ↗
2022-FY$10M$33M$60M$23M-$66M operating cash flowreport ↗
2021-FY$7.5M$53M$137M$25M-$107M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 30 purchases ($37.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-04-10George Gregory · director, 10% ownerOpen-market purchase2,324,072$1.48$3.4MForm 4
2026-04-10George Gregory · director, 10% ownerOpen-market purchase2,324,072$1.48$3.4MForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase886,890$1.43$1.3MForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase105,000$1.46$153KForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase500,000$1.44$720KForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase10,000$1.44$14KForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase4,760$1.44$7KForm 4
2026-04-09George Gregory · director, 10% ownerOpen-market purchase20,000$1.43$29KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 68 reporting institutions held 3.3M shares ($49.9M, 2.5% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.630,855$9.7M
2MORGAN STANLEY514,431$7.9M
3GOLDMAN SACHS GROUP INC397,215$6.1M
4SUSQUEHANNA INTERNATIONAL GROUP, LLP386,472$5.9M
5UBS Group AG132,573$2.0M
6BANK OF AMERICA CORP /DE/100,004$1.5M
7JANE STREET GROUP, LLC98,786$1.5M
8Penbrook Management LLC87,075$1.3M
9CITADEL ADVISORS LLC85,959$1.3M
10GROUP ONE TRADING LLC83,915$1.3M
11M&G PLC59,100$887K
12LPL Financial LLC49,617$763K
13Rialto Wealth Management, LLC46,500$715K
14LAZARI CAPITAL MANAGEMENT, INC.46,121$709K
15Fi3 FINANCIAL ADVISORS, LLC42,015$646K